Chronic Exposure Nephrotoxicity Assay: A combined (HCS) approach using (RPTEC)

Detect therapeutically relevant pathophysiological nephrotoxicity of novel therapeutics using Cyprotex’s multi-parametric high content screening (HCS) human nephrotoxicity assay.

Cyprotex delivers consistent, high quality data with the flexibility to adapt protocols based on specific customer requirements.

• Drug-induced nephrotoxicity (DIN) is a leading cause of renal failure in the clinic; creating a major concern within drug discovery programs.
• Being a highly structured filtration network, with a rich blood flow, the kidney is often exposed to high concentrations of drugs and/or metabolites creating vulnerability to drug induced toxicity¹.
• Renal proximal tubule epithelial cells RPTEC are the predominant cell type in the kidney proximal tubule and one of the main sites for re-absorption and drug accumulation often resulting in tubular damage by interfering with mitochondrial function, impairing tubular transport, increasing oxidative stress or forming free radicals^1,2,3.
• A combined high content screening (HCS) approach allows a measure of multiple cell health markers including glutathione content (GSH), phospholipidosis (PLD), mitochondrial mass (mito mass) and mitochondrial membrane potential (MMP) alongside cellular ATP levels in a kidney relevant in vitro cell model in order to better predict drug induced nephrotoxicity (DIN).

_{1) Pazhayattil GS and Shirali AC (2014). Drug-induced impairment of renal function. Int J Nephrol Renovascular Dis 7; 457-468
2) Naughton CA (2008). Drug-induced nephrotoxicity. Am Fam Physician 78(6): 743-750
3) Ozer JS et al. (2010). A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 25(5): 486-494}